🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
HLB Life Science Co., Ltd. (KOSDAQ:067630)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,290.00
-60.00 (-2.55%)
Nov 18, 2026, 3:30 PM KST

HLB Life Science Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
55,98845,75232,77197,99099,59153,494
Other Revenue
----00
55,98845,75232,77197,99099,59153,494
Revenue Growth
24.82%39.61%-66.56%-1.61%86.17%-41.73%
Cost of Revenue
61,74846,47436,40598,915102,81359,155
Gross Profit
-5,760-721.6-3,634-925.04-3,222-5,661
Selling, General & Admin
13,01713,85512,45815,22610,8398,247
Research & Development
4,5784,6975,1775,4544,3493,846
Amortization of Goodwill & Intangibles
287.42454.32182.4990.25591.418.01
Other Operating Expenses
432.72382.1351.11279192.67113.46
Operating Expenses
19,58020,31416,35024,56816,72812,668
Operating Income
-25,340-21,035-19,984-25,493-19,950-18,329
Interest Expense
-11,872-11,744-16,798-21,650-9,870-1,256
Interest & Investment Income
4,2772,2411,3561,2881,203512.76
Earnings From Equity Investments
692.992,4061,354-2,5372,602-
Currency Exchange Gain (Loss)
203.47-169.5121.23-93.2233.77-4.05
Other Non Operating Income (Expenses)
-3,409372.86101.69469.76-2,664-60.63
EBT Excluding Unusual Items
-35,447-27,928-33,848-48,015-28,646-19,137
Gain (Loss) on Sale of Investments
-2,764-63,32961,65281,336-20,548-21,296
Gain (Loss) on Sale of Assets
-3,093-3,23610.31-304.963,157594.55
Asset Writedown
-6,073-6,073-24,162-37,553-14,802-13,786
Other Unusual Items
75.03---1,966--
Pretax Income
-47,302-100,5663,652-6,503-60,839-53,624
Income Tax Expense
-1,013-666.74-3,058-590.06-6,479-4,333
Earnings From Continuing Operations
-46,289-99,8996,710-5,913-54,360-49,292
Earnings From Discontinued Operations
23,390-44.95-503.11---
Net Income to Company
-22,899-99,9446,207-5,913-54,360-49,292
Minority Interest in Earnings
52.99149.97-68.89-70.3582.24139.89
Net Income
-22,846-99,7946,138-5,983-54,277-49,152
Net Income to Common
-22,846-99,7946,138-5,983-54,277-49,152
Net Income Growth
------
Shares Outstanding (Basic)
12212211310210199
Shares Outstanding (Diluted)
12212211310210199
Shares Change
-1.87%8.11%10.73%0.80%1.64%0.34%
EPS (Basic)
-187.36-819.0754.46-58.79-537.56-494.76
EPS (Diluted)
-187.66-819.3754.46-59.00-537.56-494.76
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-37,185-48,515-59,301-30,634-40,420-16,505
Free Cash Flow Per Share
-304.96-398.19-526.20-300.99-400.32-166.14
Gross Margin
-10.29%-1.58%-11.09%-0.94%-3.23%-10.58%
Operating Margin
-45.26%-45.98%-60.98%-26.02%-20.03%-34.26%
Profit Margin
-40.80%-218.12%18.73%-6.11%-54.50%-91.88%
Free Cash Flow Margin
-66.42%-106.04%-180.96%-31.26%-40.59%-30.85%
EBITDA
-16,525-15,788-14,083-17,797-14,727-15,845
EBITDA Margin
-29.52%-34.51%-42.97%-18.16%-14.79%-29.62%
D&A For EBITDA
8,8155,2475,9017,6965,2232,484
EBIT
-25,340-21,035-19,984-25,493-19,950-18,329
EBIT Margin
-45.26%-45.98%-60.98%-26.02%-20.03%-34.26%
Advertising Expenses
-70.4996.93157.8669.1334.92